We've found
954
archived clinical trials in
Fibromyalgia
We've found
954
archived clinical trials in
Fibromyalgia
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Updated: 3/27/2018
An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia
Status: Enrolling
Updated: 3/27/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients
Updated: 4/23/2018
A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Status: Enrolling
Updated: 4/23/2018
Click here to add this to my saved trials